Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

MDUFA V Passed By US House Health Subcommittee

Executive Summary

The user fee package was among several health-related bills that the subcommittee took up on Wednesday.

You may also be interested in...



User-Fee Renewal Passes US House, 392-28

The legislative package, which sets user-fee amounts through 2027, funds a bevvy of FDA activities and improvements.

FDA Considers New Regulatory Pathways For Some Cellular Products

The US agency is re-evaluating its criteria for certain human cells, tissues and cellular and tissue-based products (HCT/Ps) that are not ideally regulated as BLAs. A 2014 guidance on cord blood products could serve a template, industry suggests.

QUOTED. Cathy McMorris-Rodgers.

US House of Representatives Energy and Commerce committee ranking member Rep. Cathy McMorris-Rodgers, R-WA, raised questions about the $3bn earmarked for new health research agency ARPA-H during user fee hearings on 11 May.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT145403

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel